Developing as a noteworthy breakthrough in the battle against obesity, the drug is generating considerable attention . It combines properties of two established GLP-1 receptor agonists, liraglutide, plus an new glucose-dependent hormonal component. Initial clinical data have indicated impressive fat reduction in patients with a high BMI , possibly